SCHEMBL3071016

SCHEMBL3071016

CC(=O)CC(=O)CC(=O)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.64
MEN1 O00255 2/20 0.64
CYP3A4 P08684 2/20 0.64
HPGD P15428 2/20 0.64
MAPK1 P28482 2/20 0.64
MAPT P10636 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
CES1 P23141 2/20 0.64
KDM4E B2RXH2 1/20 0.64
ALOX15 P16050 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
PTPN1 P18031 2/20 0.55
ERCC5 P28715 1/20 0.55
FEN1 P39748 1/20 0.55
ALDH1A1 P00352 3/20 0.52
HIF1A Q16665 2/20 0.52
PLOD2 O00469 2/20 0.52
CYP2C19 P33261 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11373627 0.89 KMT2A (0.73) KMT2AMEN1CYP3A4HPGDMAPK1
Benzene SCHEMBL8209405 0.89 KMT2A (0.73) KMT2AMEN1CYP3A4HPGDMAPK1
SCHEMBL15116 0.89 KMT2A (0.73) KMT2AMEN1CYP3A4HPGDMAPK1
Hydrogen Peroxide SCHEMBL28455182 0.89 KMT2A (0.73) KMT2AMEN1CYP3A4HPGDMAPK1
SCHEMBL1977011 0.89 KMT2A (0.80) KMT2AMEN1CYP3A4HPGDMAPK1
SCHEMBL3201635 0.87 KMT2A (0.70) KMT2AMEN1CYP3A4HPGDMAPK1
SCHEMBL21597904 0.87 KMT2A (0.70) KMT2AMEN1CYP3A4HPGDMAPK1
SCHEMBL21597902 0.87 KMT2A (0.70) KMT2AMEN1CYP3A4HPGDMAPK1
SCHEMBL3071951 0.87 KMT2A (0.70) KMT2AMEN1CYP3A4HPGDMAPK1
SCHEMBL6319140 0.87 KMT2A (0.70) KMT2AMEN1CYP3A4HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5877210-A CONTROLLING IMMUNE RESPONSE BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-02 US claimed
US-5583242-A VANADYL COMPLEXES BRISTOL-MYERS SQUIBB COMPANY (US) 1996-12-10 US claimed
US-5565491-A FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-15 US claimed
US-20250388874-A1 FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY GENOMATICA INC (US) 2025-12-25 US disclosed
US-20250290048-A1 FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY CREO INGREDIENTS, INC. 2025-09-18 US disclosed
US-20250179541-A1 METHOD OF PRODUCING CANNABINOIDS CREO INGREDIENTS, INC. 2025-06-05 US disclosed
US-20230332193-A1 FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY CREO INGREDIENTS, INC. 2023-10-19 US disclosed
US-20230241078-A1 Vanadyl and vanadate for use in reducing stress-induced metabolic derangement CFM PHARMA HOLDING B.V. (NL) 2023-08-03 US disclosed
CN-113631136-A Primer and kit of primer and dental material 凯滕巴赫股份两合公司 2021-11-09 CN disclosed
US-20200246352-A1 Vanadyl and vanadate for use in reducing stress-induced metabolic derangement CFM PHARMA HOLDING B.V. (NL) 2020-08-06 US disclosed
EP-3684352-A1 VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT CFM Pharma Holding BV (NL) 2020-07-29 EP disclosed
WO-1995020390-A1 USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION BRISTOL-MYERS SQUIBB COMPANY (US) 1995-08-03 WO disclosed
EP-0031637-B1 IMPROVEMENTS IN OR RELATING TO FILLED POLYMERIC COMPOSITIONS, HYDRATED ALUMINA FILLERS THEREFOR AND PROCESSES FOR THE PRODUCTION THEREOF RAYCHEM LIMITED (GB) 1984-10-03 EP disclosed
US-4396589-A Alkali metal complex compounds, and their use in the hydrogenation and nitridation of alkali metals STUDIENGESELLSCHAFT KOHLE MBH (DE) 1983-08-02 US disclosed
US-4382983-A PARTIALLY HYDROLYZED SILOXANE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1983-05-10 US disclosed
US-4370488-A CATALYSTS FOR HYDROGENATION OF ALFALI METALS STUDIENGESELLSCHAFT KOHLE MBH (DE) 1983-01-25 US disclosed
US-4330637-A Encapsulated electronic devices and encapsulating compositions WESTERN ELECTRIC COMPANY, INC. (US) 1982-05-18 US disclosed
US-4301081-A FOR USE AS CATALYST FOR HYDROGENATION OF ALKALI METALS TO HYDRIDES OR NITRIDES STUDIENGESELLSCHAFT KOHLE MBH (DE) 1981-11-17 US disclosed
EP-0031637-A2 Improvements in or relating to filled polymeric compositions, hydrated alumina fillers therefor and processes for the production thereof RAYCHEM LIMITED (GB) 1981-07-08 EP disclosed
US-4229354-A COMPLEXING WITH COMPOUNDS OF SULFUR OR OXYGEN STUDIENGESELLSCHAFT KOHLE MBH (DE) 1980-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388874-A1 FLAVIN-DEPENDENT OXIDASES HAVING CANNABINOID SYNTHASE ACTIVITY BLVRB, SQOR, CYP2F1 KMT2A 3075/4885MEN1 3893/4885CYP3A4 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.